Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of GLPG1690 Tablet vs Capsule and Food Effect
NCT03143712Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Apr 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ziritaxestat in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Galapagos NV. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Time to Reach Maximum Observed Plasma Concentration at 48 hours and 1 more. Started Apr 2017; status: completed.
02
Drugs
ziritaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03143712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03143712.